|
 A. Donny Strosberg is Professor of Infectology at The Scripps Research Institute in Florida where he manages a program on Hepatitis C. His current work focuses on developing novel small molecule therapeutics based on inhibition of protein-protein interactions (see recent papers: Kota et al. 2009a, Kota et al.2009b, and Wei et al. 2009). His group also develops a new infectious HCV genotype 1b culture system which is resistant to interferon.
Prof. Strosberg was trained as a Dr. Sci at the Free University of Brussels and did a post-doctoral fellowship at Massachusetts General Hospital in Boston. After serving at the Harvard Medical School as an Instructor and later as a Visiting Professor, he became Professor of Biochemistry and Immunology first in Brussels, then in Paris. With his teams he published over 360 peer-reviewed original scientific articles, several books and dozens of book chapters. He authored over twenty issued patents of which several were licensed to pharmaceutical companies. Prof. Strosberg is a co-founder of several biotechnology companies including Chemunex, co-founded with the University of Paris; Incyte, Praecis, co-founded with M.I.T.; BioRelix co-founded with Yale University; and most recently Protix Therapeutics, co-founded with The Scripps Research Institute. From 1998 to 2004 Prof. Strosberg was the Chairman and CEO of Hybrigenics, a company, which he co-founded with the Pasteur Institute from 1998 to 2004. Media June 2010 Breaking Hepatitis C's Shell What might prompt a successful, respected French biotech CEO raising $60 million a year for his company to give it all up and move to Florida to work for a non-profit? For Donny Strosberg it was one question: "They asked me, 'What is the most difficult (problem) that you think you could solve?'" Strosberg recalled.
Hepatitis C, one of the main causes of liver cancer, was where he longed to make a difference. In 2005, Strosberg uprooted his life and moved to Scripps Florida, where he is tackling the problem full-speed-ahead. January 25, 2010 Team Identifies Novel Hepatitis C Inhibitors Scientists from the Scripps Florida campus of The Scripps Research Institute and their colleagues at Boston University have described their discovery of several novel drug-like inhibitors of the hepatitis C virus (HCV). These new inhibitors have the potential to substantially widen the current options to treat HCV infection. December 16, 2009 Scripps Research Scientists Identify Novel Hepatitis C Inhibitors Discovery Opens Door to Research on New Type of Therapeutic Compounds Scientists from the Scripps Florida campus of The Scripps Research Institute and their colleagues at Boston University have described their discovery of several novel drug-like inhibitors of the hepatitis C virus (HCV). These new inhibitors have the potential to substantially widen the current options to treat HCV infection. November 16, 2009 Donny Strosberg gave up fame in France to join Scripps to help fund cures for diseases in South Florida Challenges can make people crumble and surrender or spur them to fight harder to succeed. Donny Strosberg, a biochemist at The Scripps Research Institute's Florida campus in Jupiter, falls into the later category. March 9, 2009 Scripps Research Team Identifies Key Molecules that Inhibit Viral Production A team from The Scripps Research Institute has found a way to inhibit viral production of the Hepatitis C virus (HCV). The advance has the potential to accelerate future research on the virus life cycle and to aid in the development of novel HVC drugs. The Promise: Boca News Recently three local high school students and three local returning university students completed a Scripps Florida summer intern program at the Scripps Florida facilities on the Florida Atlantic University (FAU) in Jupiter. |
